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Abstract 
Malignant brain tumors including medulloblastomas and primitive neuroectodermal 
tumors (PNETs) have a low 5-year relative survival rate of around 50%, and are among the most 
common solid cancers in children[1][2]. Mutations in DNA mismatch-repair (MMR) genes, such 
as MSH6 (MutS Homolog 6), have been observed in many types of human cancers, including 
malignant brain tumors[1]. This study is focused on understanding the contribution of DNA-
repair towards malignancy of pRB (retinoblastoma tumor suppressor protein) defective brain 
tumors. To study this interaction, I used CRISPR-Cas9 gene editing to disrupt the MSH6 gene (a 
key DNA MMR gene commonly mutated in brain cancers) in rb1- mutant zebrafish embryos, 
followed by analysis through sectioning, histological staining, and confocal imaging of the 
mutant and control zebrafish larvae. A longer-term goal for this project would be to test for the 
cooperativity of rb1 tumor suppressor and DNA repair in tumor malignancy by co-injecting 
gRNAs targeting rb1 and MSH6 into wildtype zebrafish embryos. 
 
 
 
 
 
Introduction 
Statistical data has shown that malignant brain tumors such as medulloblastomas and 
primitive neuroectodermal tumors (PNETs) are the most common solid cancers in children[1]. 
The 5-year relative survival rate from the point of diagnosis is around 50%, which is quite low 
making it a prime area of study[2]. Many efforts are being made to understand the onset and 
proliferation of pediatric brain tumors. The main goal of this project is to study the contribution 
of DNA repair towards malignancy of cells. This interaction was investigated by disrupting 
MSH6 (MutS Homolog 6), a key DNA mismatch repair gene, in a zebrafish model for pediatric 
brain cancer developed by the McGrail Lab[3]. 
The reason for choosing zebrafish is that it is a great model biological system for study of 
human disease, especially brain tumors. The zebrafish genome is well understood and has been 
fully sequenced. Also, there are various molecular tools already in place to modify, analyze, and 
study genetic interactions in zebrafish. Moreover, zebrafish have relatively large and transparent 
embryos facilitating injections in the single-cell stage, and observation of phenotypes. Most 
importantly, they are inexpensive, easy to maintain, fecund, and have a fast generation time.[4] 
Our model of human PNET brain tumors was generated in the McGrail lab, by somatic 
inactivation of the retinoblastoma tumor suppressor gene (rb1). Genetic mosaic adults developed 
brain tumors that histologically resemble human PNET tumors. Transcriptome analysis of the 
rb1- brain tumors showed a molecular signature of neural progenitor cells, and the rb1-/- 
homozygous mutants exhibited overproliferation brain phenotype at day 5[3]. 
MutS Homolog 6 (MSH6) is a DNA mismatch repair (MMR) gene. During DNA 
replication, small errors are often overlooked by the in-built proof reading mechanism. These 
errors are corrected by MMR genes including MSH6[5]. Defects in MMR genes increase mutation 
production in living cells by 100-1000 fold, leading to many types of human cancers[1]. 
Moreover, increased expression [Figure 1] of MSH6 was observed in the tumor transcriptome of 
the rb1- PNET brain tumor model developed by the McGrail lab[3]. 
The loss of the pRB tumor suppressor primes cells to divide uncontrollably due to 
inactivation of a critical cell cycle checkpoint[6]. In the embryo, lack of pRB results in 
overproliferation of cells in the developing brain, normally destined to become neurons. So, I 
hypothesized that the additional loss of the MSH6 DNA repair gene in pRB mutants will 
suppress or reduce the overproliferation of cells in the brain. The objective of this experiment 
was therefore to mutate the MSH6 DNA mismatch repair gene in zebrafish, using the CRISPR-
Cas9 system, in order to study the role of DNA repair in cellular transformation and 
tumorigenesis.  
                      
Figure 1. Heat map showing elevated expression of MMR genes in rb1- zebrafish brain tumors 
 
 
 
Methods 
Mutation of MSH6 was achieved using the CRISPR-Cas9 system. CRISPR-Cas9 is a 
genome editing technology that uses a small RNA as a guide to target the Cas9 enzyme to a 
specific location in DNA. Cas9 creates breaks at the target site in the DNA. During imprecise 
repair of the DNA insertion and deletions mutations are introduced[7]. The first step was the 
design and optimization of oligonucleotides to synthesize guide RNAs to target the MSH6 gene. 
Guide RNAs (gRNAs) are short RNA sequences that guide insertions or deletions of nucleotides 
at targeted sites in the gene. The gRNAs were designed to target downstream and upstream exons 
(exons 2 and 9) in the MSH6 gene. The gRNAs along with CRISPR-Cas9 mRNA were injected 
into single celled zebrafish embryos, in order to induce somatic mutations. This process causes 
the DNA to be cut at the target locations by the Cas protein, and the two extreme ends of the 
gene are ligated (joined)[6]. PCR amplification of the product followed by gel electrophoresis and 
subsequent sequencing of the DNA showed loss of a majority of the MSH6 gene fragment 
(approx. 13.6 kb deletion), disrupting its function [Figure 2]. Once this was established and there 
was evidence that the gRNAs and CRISPR Cas system was efficient in mutagenesis, the gRNAs 
along with CRISPR-Cas9 mRNA were injected into 40 single celled zebrafish embryos obtained 
from rb1 +/- (heterozygotes) incross. Another 30 uninjected embryos were collected to serve as 
uninjected controls.  
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Figure 2. MSH6 gene diagram with CRISPR target sites 
	
Five days post fertilization, each larva was tested for MSH6 mutagenesis and genotyped 
for rb1, by PCR amplification followed by gel electrophoresis and sequencing of selected 
samples [Figure 3]. The genotyped larvae were grouped, and the heads embedded into blocks 
(injected & uninjected, rb1-/+, +/+, -/-). Two sets of three heads for each of the three genotypes 
were embedded to get a total of six blocks. Once each of the rb1+/+ (wildtype) and rb1-/- tissue 
blocks was sectioned using a cryostat at -20°C, and the 16um thick sections were mounted on 
slides. Sections of the entire brain starting from the forebrain through the hindbrain were 
collected on five slides (per block), such that each slide had six sections (forebrain through 
hindbrain).  
     
IHC (immunohistochemistry) was then used to label the tissue with DAPI, to count total 
number of cells (stains all nuclei); & phosphohistone-3 (PH3) to count mitotic figures (stains 
only proliferating cells). Overproliferation can be visualized by the presence of multiple mitotic 
figures, which indicate cell proliferation by mitotic cell division. The stained tissue sections 
(midbrain/ optic tectum) were imaged using a confocal microscope. The images were analyzed 
for changes in proliferation and obtained mitotic (PH3) cell counts using ImageJ software. The 
data from the cell counts was interpreted and compared using the GraphPad Prism program and 
p-values were calculated from the student’s t-test. This entire experiment was replicated and 
repeated twice, to get a total of three sets of data. 
 
Results/ Discussion 
From the confocal image analysis [Figure 4], it can be observed that the wildtype 
(rb1+/+) brains showed almost no mitotic/ proliferating cells, as expected. The rb1-/- 
homozygous loss-of-function mutants exhibit overproliferation, as anticipated. In rb1- mutant 
brains, regions that are normally post mitotic, contain proliferating cells indicating that cells are 
not differentiating normally. The data reflects a slightly higher proliferation in injected (MSH6 
mutant) rb1-/- compared to the uninjected rb1-/-. However this difference is not statistically 
significant as the p-value (= 0.40) from the student’s t test is greater than 0.05. The injected 
rb1+/+ (wildtype) group shows a slight increase in proliferation compared to the uninjected 
rb1+/+. This difference is also not statistically significant as the p-value (= 0.27 ) is greater than 
0.05. Similar results were observed even from the cell counts of the brain alone (excluding 
retinas).  
The results are not statistically significant, hence the hypothesis that additional loss of the 
MSH6 DNA repair gene in pRB mutants will suppress or reduce the overproliferation of cells in 
the brain, cannot be rejected. A possible explanation for the low statistical significance is that the 
MSH6 gene is part of a family of DNA MMR genes, which may have redundant functions. 
Hence another MMR gene may have compensated for the loss of MSH6 gene function, thereby 
resulting in a statistically insignificant difference in proliferation. Hence, The next step of this 
experiment would be to target multiple MMR genes in order to be able to observe a more 
pronounced and significant effect on proliferation in rb1 mutant fish. 
 
Figure 4. Confocal Images showing mitotic/ proliferating cells (green) 
 
Work in Progress/ Future Plans 
I have successfully isolated stable germline mutants with 16bp and 22bp deletions in 
MSH6 (exon 2); and rb1-/MSH6- double heterozygous mutants. A longer-term goal of the project 
is to test cooperativity for rb1 tumor suppressor and DNA repair in tumor malignancy. This can 
be tested by simultaneously targeting mutations to MSH6 and rb1 in wildtype embryos and 
determining if the age of onset and/or frequency of individual fish with tumors is affected. At 
present we know that 50% of the adults with a somatic mutation for rb1 will develop brain 
tumors by 5 months of age. The somatic rb1 mutants will be tested for early tumor formation 
when the DNA repair machinery is also disrupted by the somatic mutation of MSH6. The fish 
will be examined for tumor phenotype at 2, 3, 4 and 5 months, by using histological markers and 
proteins that are specific to neurons and glial cells, in order to characterize the tumors as 
primitive or glial-like. Other approaches to test for pRB and MSH6 cooperativity in brain tumor 
formation is to inject gRNAs targeting mutations in rb1 into stable MSH6 germline deletion 
embryos, or generating double homozygous mutants for MSH6 & rb1. 
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